Top 100 Shareholders as at 31 October 2022 with variations, page-10

These are the performance rights that are still in play IF RM is still technically employed by PAA for the 6 month period since his notice on 27^th May:

A)

1,000,000 Upon the formal commencement by PharmAust Limited
of a Phase II trial in humans of monepantel as a
treatmentin neuro-degenerative disease either alone or
in combination with other drugs at one or more
approved centres in Australia or the United States or
United Kingdom following commencement of all formal
approvals from relevant regulators and entities and the
recruitment of the first patient.

End date: 31 October2022

B)

1,000,000 Upon the formal commencement by PharmAust Limited
of a Phase II trial in humans of monepantel as an anti-
cancer treatment either alone or in combination with
other drugs either at one or more approved centres in
Australia or the United States or United Kingdom
following commencement of all formal approvals from
relevant regulators and entities and the recruitment of
the first patient.

End Date 31 October2022

Fairly safe to say neither of these will be hit.